文献速递血栓与止血

美国非重型血友病A患者抑制剂与死亡率研究

Inhibitors and mortality in persons with nonsevere hemophilia A in the United States.
PubMed 文献 · Blood Adv · 2020-01-01

该研究基于美国血栓与止血网络数据集,纳入6624例非重型血友病A患者,随访9年(2010-2018),观察抑制剂状态与死亡风险。抑制剂患病率为2.6%,中位发生年龄13岁;抑制剂存在与死亡风险增加无关(HR 0.7,95%CI 0.2-2.3)。年龄、男性、丙肝和HIV感染与死亡风险独立相关。

要点

  • 非重型血友病A患者抑制剂患病率2.6%,中位发生年龄13岁。
  • 抑制剂存在未增加死亡风险(HR 0.7,95%CI 0.2-2.3)。
  • 年龄、男性、丙肝和HIV感染是死亡风险独立预测因素。

核心结论

  • 在非重型血友病A患者中,抑制剂发生年龄早且与死亡率增加无关。

主要发现

  • 抑制剂患病率为2.6%(n=171),中位发生年龄13岁。
  • 随访结束时136例死亡,中位死亡年龄63岁,年龄调整死亡率为3.3例/1000人年。
  • 抑制剂存在与死亡风险无关(HR 0.7,95%CI 0.2-2.3)。
  • 死亡风险独立相关因素:年龄每增加10岁(HR 2.1,95%CI 2.0-2.4)、男性(HR 2.6,95%CI 1.0-6.4)、丙肝(HR 2.2,95%CI 1.5-3.1)、HIV(HR 3.6,95%CI 2.2-6.0)。
  • 最常见主要死因为恶性肿瘤(n=27,20.0%)。

临床怎么用

  • 对非重型血友病A患者应关注抑制剂发生,但抑制剂本身不增加死亡风险。
  • 临床管理应重视年龄、男性、丙肝和HIV感染等死亡风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although persons with nonsevere hemophilia A (NSHA) account for about one-half of the hemophilia A population, epidemiological data in this subset of individuals are scarce. We set out to describe the clinical characteristics of persons with NSHA with inhibitors, and to determine mortality rates, predictors of mortality, and primary causes of death in persons with NSHA in the United States over a 9-year period (2010-2018). We queried the American Thrombosis and Hemostasis Network dataset (ATHNdataset) for information on demographics, inhibitor status, and date and cause of death. A total of 6624 persons with NSHA (86.0% men; 14.0% women) were observed for an average of 8.5 years; total 56 119 person-years . The prevalence of inhibitors was 2.6% (n = 171), occurring at a median age of 13 years. At the end of follow-up, 136 persons died at a median age of 63 years; an age-adjusted mortality rate of 3.3 deaths per 1000 person-years. Three deaths occurred in inhibitor participants. Presence of inhibitors was not associated with increased mortality risk (hazard ratio [HR], 0.7, 95% confidence interval [CI], 0.2-2.3). Factors independently associated with increased risk of death (HR, 95% CI) were the following: age (10-year increase) (2.1, 2.0-2.4); male (2.6, 1.0-6.4); hepatitis C (2.2, 1.5-3.1); and HIV (3.6, 2.2-6.0). The most common primary cause of death was malignancy (n = 27, 20.0%). In persons with NSHA, the development of inhibitors occurred at an early age and was not associated with increased mortality.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lim MY, Cheng D, Recht M, et al. Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. Blood Adv. 2020. PMID: 33007074. doi:10.1182/bloodadvances.2020002626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。